- Home
- ATNM vs CNTB Comparison
ATNM vs CNTB Comparison
Compare ATNM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- CNTB
- Stock Information
- Founded
- ATNM 2000
- CNTB 2012
- Country
- ATNM United States
- CNTB United States
- Employees
- ATNM N/A
- CNTB N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- CNTB Health Care
- Exchange
- ATNM Nasdaq
- CNTB Nasdaq
- Market Cap
- ATNM 56.5M
- CNTB 53.9M
- IPO Year
- ATNM N/A
- CNTB 2021
- Fundamental
- Price
- ATNM $1.40
- CNTB $1.05
- Analyst Decision
- ATNM Strong Buy
- CNTB Strong Buy
- Analyst Count
- ATNM 4
- CNTB 1
- Target Price
- ATNM $8.75
- CNTB $8.00
- AVG Volume (30 Days)
- ATNM 342.1K
- CNTB 28.0K
- Earning Date
- ATNM 11-14-2024
- CNTB 09-05-2024
- Dividend Yield
- ATNM N/A
- CNTB N/A
- EPS Growth
- ATNM N/A
- CNTB N/A
- EPS
- ATNM N/A
- CNTB N/A
- Revenue
- ATNM $81,000.00
- CNTB $24,116,000.00
- Revenue This Year
- ATNM $138.42
- CNTB N/A
- Revenue Next Year
- ATNM $19,479.88
- CNTB $63.90
- P/E Ratio
- ATNM N/A
- CNTB N/A
- Revenue Growth
- ATNM N/A
- CNTB N/A
- 52 Week Low
- ATNM $1.10
- CNTB $0.90
- 52 Week High
- ATNM $10.24
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- ATNM 56.03
- CNTB 45.74
- Support Level
- ATNM $1.18
- CNTB $1.01
- Resistance Level
- ATNM $1.48
- CNTB $1.40
- Average True Range (ATR)
- ATNM 0.10
- CNTB 0.13
- MACD
- ATNM 0.01
- CNTB -0.01
- Stochastic Oscillator
- ATNM 75.00
- CNTB 25.53
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.